Vitamin K2 supplier NattoPharma sponsored a survey in which a significant percentage of respondents were interested in maintaining arterial health.
Photo © iStockphoto.com/jasminam
A new survey on 380 consumers indicates that a significant percentage are interested in maintaining arterial health. Up to 35% of those surveyed said they were very concerned that hardening of arteries would negatively impact their heart health, while 67% said they would take a supplement to reduce the chances of arteries hardening. They said they would do this if the supplement had no side effects and was cost-comparable with other heart-health supplements.
Discovery Research Group conducted the survey in October 2015 on behalf of NattoPharma USA Inc. (Metuchen, NJ), a supplier of vitamin K2 MK7 ingredients. Last year, the company announced the first study (three-year; 244 subjects) showing that supplementing with NattoPharma’s MenaQ7 ingredient improved arterial stiffness in postmenopausal women.
In the recent survey, 25% of respondents identified themselves as having a condition associated with heart disease, while 40% had someone in their immediate family with a condition associated with heart disease; of those (the survey respondents or their family members), 84% were currently taking a prescription medicine and 44% took a supplement. Also, among 30- to 40-year-olds surveyed, supplementation was named the number-one action respondents would take if they developed a heart disease. Overall, on a scale of 1–7, 62% of survey respondents rated their level of concern about heart health overall as 5 or greater.
“Just over one-third of survey participants ranked ‘hardening of arteries’ as one of the top-three risk factors associated with heart disease,” said Eric Anderson, senior vice president of global sales and marketing, NattoPharma, in a press release announcing the results. He added that MenaQ7 “not only protects against age-related hardening of the arteries and regressed arterial stiffening, but it also has been shown to improve bone mineral density and strength.”
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine
jennifer.grebow@ubm.com
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.